Search - tctmd.com

Displaying 181 - 200 of 375

Sort: Relevancy | Date

Presentation TCT 2017

REDUCE: A Randomized Trial of 3-Month vs 12-Month DAPT After Implantation of a Bioabsorbable Polymer-Based Metallic DES With a Luminal CD34+ Antibody Coating in Patients With ACS

Presenter: Robert A. Harrington, Gregg W. Stone, Harry Suryapranata

November 01, 2017

Presentation TCT 2017

DAPT STEMI: A Randomized Trial of 6-Month vs 12-Month DAPT After DES Implantation in STEMI

Presenter: Robert A. Harrington, Gregg W. Stone, Elvin Kedhi

November 01, 2017

Presentation TCT 2017

SENIOR: A Randomized Trial of a Bioabsorbable Polymer-Based Metallic DES vs a BMS With Short DAPT in Patients With Coronary Artery Disease Older Than 75 Years

Presenter: Robert A. Harrington, Gregg W. Stone, Olivier Varenne

November 01, 2017

Presentation TCT 2017

Adjunctive Pharmacotherapy after TAVR Settled and Unsettled Issues

Presenter: Charles J. Davidson, Mathew Williams, Luis Nombela-Franco

November 01, 2017

Presentation TCT 2017

What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis

Presenter: Azeem Latib, Gregg W. Stone

October 31, 2017

Presentation TCT 2017

FDA Perspectives on Short DAPT IDE Trials

Presenter: Mitchell W. Krucoff, P.F. Adrian Magee

October 31, 2017

Presentation TCT 2017

The High-Bleeding-Risk Patient: Physician-Scientist Perspectives on Standard vs Novel DES and DAPT Duration

Presenter: Mitchell W. Krucoff, P.F. Adrian Magee, Ajay J. Kirtane

October 31, 2017

Presentation TCT 2017

The High-Bleeding-Risk Patient: Physician-Scientist Perspectives on Appropriate Patients and DAPT Duration

Presenter: Mitchell W. Krucoff, P.F. Adrian Magee, Marie-Claude Morice

October 31, 2017

Presentation TCT 2017

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Fabiana Rollini

October 30, 2017

Presentation TCT 2017

Impact of Race and Sex on Platelet Reactivity and Clinical Implications

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Ron Waksman

October 30, 2017

Presentation TCT 2017

Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More)

Presenter: Robert A. Byrne, Gregg W. Stone, Robert A. Harrington

October 30, 2017

Presentation TCT 2017

The Inflammatory Hypothesis After CANTOS: CIRT

Presenter: Bernard J. Gersh, Robert A. Harrington, Wolfgang Koenig

October 30, 2017

Presentation TCT 2017

The LDL Hypothesis Post FOURIER: Heading Home From ODYSSEY

Presenter: Bernard J. Gersh, Robert A. Harrington, Wolfgang Koenig

October 30, 2017

Presentation

Association Between Use of Antithrombotic Medication and Hematuria-Related Complications

October 09, 2017

Presentation CDM 2017

Can Heart Disease be Eventually Abolished? The PCSK9 Revolution

Presenter: Robert A. Vogel

October 06, 2017

Presentation VIVA 2017

What is the Right Antiplatelet Therapy for Symptomatic Carotid Disease?

Presenter: William Gray

September 21, 2017

Presentation VIVA 2017

Is Aspirin Really a Class I Medication in Peripheral Artery Disease?

Presenter: Ehrin J. Armstrong

September 19, 2017

Presentation Fellows 2017

STEMI: Treatment Strategies, Drugs And Devices

Presenter: Dharam J. Kumbhani

August 30, 2017

Presentation iASSESS 2017

NSTEACS: Risk Stratification and Treatment

Presenter: Dmitriy N. Feldman

August 30, 2017

Presentation iASSESS 2017

Aspirin and ADP Antagonists Pre and Post Coronary Stent Implantation

Presenter: Dmitriy N. Feldman

August 30, 2017

Advertisement

REDUCE: A Randomized Trial of 3-Month vs 12-Month DAPT After Implantation of a Bioabsorbable Polymer-Based Metallic DES With a Luminal CD34+ Antibody Coating in Patients With ACS

DAPT STEMI: A Randomized Trial of 6-Month vs 12-Month DAPT After DES Implantation in STEMI

SENIOR: A Randomized Trial of a Bioabsorbable Polymer-Based Metallic DES vs a BMS With Short DAPT in Patients With Coronary Artery Disease Older Than 75 Years

Adjunctive Pharmacotherapy after TAVR Settled and Unsettled Issues

What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis

FDA Perspectives on Short DAPT IDE Trials

The High-Bleeding-Risk Patient: Physician-Scientist Perspectives on Standard vs Novel DES and DAPT Duration

The High-Bleeding-Risk Patient: Physician-Scientist Perspectives on Appropriate Patients and DAPT Duration

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Impact of Race and Sex on Platelet Reactivity and Clinical Implications

Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More)

The Inflammatory Hypothesis After CANTOS: CIRT

The LDL Hypothesis Post FOURIER: Heading Home From ODYSSEY

Association Between Use of Antithrombotic Medication and Hematuria-Related Complications

Can Heart Disease be Eventually Abolished? The PCSK9 Revolution

What is the Right Antiplatelet Therapy for Symptomatic Carotid Disease?

Is Aspirin Really a Class I Medication in Peripheral Artery Disease?

STEMI: Treatment Strategies, Drugs And Devices

NSTEACS: Risk Stratification and Treatment

Aspirin and ADP Antagonists Pre and Post Coronary Stent Implantation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content